Lists of diseases

Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022

Retrieved on: 
Tuesday, October 25, 2022
Neurology, Health, Science, Pharmaceutical, Research, U.S. Securities and Exchange Commission, Risk, Therapy, Investor relations, Investor, Tablet, Tranylcypromine, Acorda Therapeutics, NASDAQ, Patient, Inhalation, Research, Security (finance), Workforce, Judgement, Lists of diseases, Technology, Goal, Nasdaq, 4-Aminopyridine, Phenelzine, Q&A, Patent, Intellectual property, Forward-looking statement, Travel, Failure, COVID-19, OFF, Consultant, ACOR, Pharmaceutical industry, Webcast

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m.
  • After you have registered, you will receive a confirmation email with the Webcast details.
  • On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join.
  • The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com .

Global Non-Opioid Pain Treatment Market Report to 2030 - Increasing Geriatric Population Leading to Rising Demand for Elderly Care Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Health, Pharmaceutical, Migraine, Arthritis, Prevalence, Growth, Research report, Fibromyalgia, CAGR, Drug development, Research, Partnership, Cancer, Forecasting, Analgesic, Acquisition, Epilepsy, Pain, Neuropathic pain, Patent, Lists of diseases, OTC, Chronic pain, Osteoarthritis, COVID-19, USD, Cereal, Dentistry

Increasing geriatric population, increasing need to improve treatments in healthcare, and growing lifestyle-associated ailments, is driving the growth of non-opioids pain treatment market.

Key Points: 
  • Increasing geriatric population, increasing need to improve treatments in healthcare, and growing lifestyle-associated ailments, is driving the growth of non-opioids pain treatment market.
  • Furthermore, increasing occurrence of chronic pain is also fueling the non-opioids pain treatment market growth.
  • Increasing spending on research and development, undergoing clinical trials, and change in the favorable regulatory policies are augmenting the growth of the non-opioids pain treatment market.
  • The report analyses the key growth drivers, opportunities and challenges which influence the Non-Opioid Pain Treatment market.

Alto Neuroscience Announces $35 Million Series B Financing

Retrieved on: 
Tuesday, October 25, 2022
Professional Services, Pharmaceutical, Data Management, Biometrics, Mental Health, Technology, Health Technology, Clinical Trials, Biotechnology, Neurology, Finance, Health, Palo Alto University, Science, Novartis Institute for Tropical Diseases, Cognition, Neuroscience, Patient, Lists of diseases, Biology, Depression, EEG, Twitter, Biomedical Research, Board, Series, Genetics, Board of directors, Brain, NIBR, PTSD, Biomarker, Pharmaceutical industry, Management

Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital, with participation from other new investors including Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, and Gaingels.

Key Points: 
  • Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital, with participation from other new investors including Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, and Gaingels.
  • The financing also included participation from existing investors Apeiron Group, WhatIf Ventures, Windham Venture Partners, and others.
  • In conjunction with the Series B financing, chief executive officer of Lightswitch Capital, Christopher Cox, and managing director of Alkeon Capital, Jeff Chen, Ph.D., have joined the Alto Board of Directors.
  • Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster.

Koneksa Announces Clinical Pipeline of Validated Digital Biomarkers to Accelerate Life Sciences Research

Retrieved on: 
Tuesday, October 25, 2022
Other Health, Other Science, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hardware, Genetics, Data Management, Science, Technology, Clinical Trials, General Health, FDA, Diabetes, Health, Health Technology, RSVP, Adoption, Interest, Montefiore Medical Center, Efficiency, Actigraphy, Multiple sclerosis, Organization, Patient, Drug development, Data, HIV disease progression rates, Multimedia, Sanofi, Partnership, Technology, The Michael J. Fox Foundation, Industry, Respiratory disease, Northwestern University, CEO, Clinical trial, One World Trade Center, Digital, Regeneron Pharmaceuticals, Gait, FDA, Lists of diseases, Solution, Biomarker, Algorithm, Medical imaging

Koneksa , a healthcare technology company developing evidence-based validated digital biomarkers, today announced the launch of its clinical pipeline featuring biomarkers across neuroscience, oncology, respiratory, and other therapeutic areas.

Key Points: 
  • Koneksa , a healthcare technology company developing evidence-based validated digital biomarkers, today announced the launch of its clinical pipeline featuring biomarkers across neuroscience, oncology, respiratory, and other therapeutic areas.
  • The launch of the clinical pipeline will enable Koneksa to expand biomarker evidence generation in the near-term and develop new digital biomarkers to support long-term industry and patient needs.
  • Koneksa has partnerships with life sciences companies, patient advocacy organizations and academic institutions on its digital biomarker pipeline.
  • Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research, guide decision-making in drug development and market strategy.

Inscopix Showcases New Products and Key Scientific Presentations from Customers at the 52nd Annual Meeting of the Society for Neuroscience

Retrieved on: 
Tuesday, October 25, 2022
Other Health, General Health, Hardware, Mental Health, Medical Devices, Technology, Genetics, Health Technology, Nanotechnology, Audio, Video, Neurology, Health, Methodology, CSO, Therapy, Hope, SFN, Scalable Urban Traffic Control, Patient, Lists of diseases, Research, Twitter, Publication, Attention, Society, Friends, Acquisition, Behavior, IDEAS, CEO, 2021 Essex County Council election, Neurodegeneration, Brain, Poster, Program, Medical imaging, Video game, Music, Neuroscience

Every day, researchers around the world are using Inscopixs technology to break new ground in understanding how the brain works.

Key Points: 
  • Every day, researchers around the world are using Inscopixs technology to break new ground in understanding how the brain works.
  • The Inscopix SfN Booth #1028 will highlight two key 2022 additions to the companys miniscope platform and applications portfolio.
  • The Inscopix booth will have scheduled demonstrations of the IDEAS Platform, sign-ups for which are currently open here .
  • Inscopix is a brain imaging platform company focused on decoding the mind to better understand and address all neurological disorders.

FDA Registers Aural Analytics Clinical-Grade Speech Analytics as a Computerized Cognitive Assessment Aid

Retrieved on: 
Tuesday, October 25, 2022
Neurology, Software, Health, Health Technology, Technology, Apps, Applications, Mobile, Wireless, Other Health, SDK, LinkedIn, API, Hearing, US Foods, Android, Patient, Twitter, IOS SDK, Food, QMS, Food and Drug Administration, CEO, IOS, Speech, FDA, Vital, Lists of diseases, Medical device, Facebook

Aural Analytics, Inc. , a leader in clinical-grade speech analytics, today announced US Food and Drug Administration (FDA) registration for its clinical-grade speech analytics product, Speech Vitals, as a computerized cognitive assessment aid, a class II software medical device (SaMD).

Key Points: 
  • Aural Analytics, Inc. , a leader in clinical-grade speech analytics, today announced US Food and Drug Administration (FDA) registration for its clinical-grade speech analytics product, Speech Vitals, as a computerized cognitive assessment aid, a class II software medical device (SaMD).
  • FDA registration strengthens Speech Vitals objective, reliable, generalizable, and repeatable approach to speech analytics, made possible by its clinically and analytically validated measures of speech.
  • Human speech relies on coordinating complex neural activity, including cognitive and motor functions, said Judy Smythe, CEO of Aural Analytics.
  • As cognitive disease develops, subtle changes in speech occur, which can be precisely detected using our powerful speech analytics.

Magellan Healthcare Launches New Senior Assistance Solution

Retrieved on: 
Tuesday, October 25, 2022
General Health, Other Health, Seniors, Consumer, Health, Trade, Health, LinkedIn, Caregiver, Time, Mental health, Senior assistant commissioner, Health care, Transport, Housing, Social support, Ferdinand Magellan, Instagram, Workforce, Department of Defense Serum Repository, Electricity, Technology, Solution, Department, Federation, CEO, Food, Forest Law Enforcement and Governance Program, Frailty, Lists of diseases, Meal, Magellan Health, Medicine, Health insurance, Ageing, Facebook, Spotify

Magellan Healthcare, Inc. , the behavioral and specialty healthcare segment of Magellan Health, Inc. , today announced the launch of their new Senior Assistance solution powered by DUOS .

Key Points: 
  • Magellan Healthcare, Inc. , the behavioral and specialty healthcare segment of Magellan Health, Inc. , today announced the launch of their new Senior Assistance solution powered by DUOS .
  • Magellan Healthcares Senior Assistance solution takes care of older adults aging needs while easing the burden on their unpaid caregivers, said Caroline Carney, M.D., Magellan Healthcares President of Behavioral Health and Chief Medical Officer of Magellan Health.
  • Through the Senior Assistance solution Magellan members receive a personalized plan and weekly virtual check-ins to help them meet ongoing and daily needs support in addressing concerns that may be preventing them from aging independently.
  • About Magellan Healthcare: Magellan Healthcare, Inc. , the healthcare business unit of Magellan Health, Inc., offers solutions for complex conditions in the areas of behavioral health and medical specialty treatment.

Merck Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Retrieved on: 
Wednesday, October 26, 2022
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SLE, SEL, Merck Serono, Union, Health, Birth, BTK, Electronics, Neuromyelitis optica spectrum disorder, MS, Interferon beta-1a, Multiple sclerosis, Science, CIS, Lupus, RRMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of diseases, Intelligence, Patient, SPMS, Gene editing, HIV disease progression rates, NMOSD, Central nervous system, Food, Human, Neurology, Cladribine, RMS, Safety, AFL, Physical disability, GMG, Hypoesthesia, DNA, FDA, Lymphocyte, Entrepreneurship, Merck Millipore, Biomarker, Neurodegeneration, Pharmaceutical industry, Merck, EU

It is currently under clinical investigation and is not approved for any use anywhere in the world.

Key Points: 
  • It is currently under clinical investigation and is not approved for any use anywhere in the world.
  • Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS).
  • The companys current MS portfolio includes two products for the treatment of relapsing MS Rebif (interferon beta-1a) and MAVENCLAD (cladribine tablets).
  • All Merck press releases are distributed by e-mail at the same time they become available on the EMD Group website.

HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Dysbiosis, Risk, Therapy, Non-alcoholic fatty liver disease, T2DM, American Association for the Study of Liver Diseases, Population, Gut microbiota, Cholestasis, Alkaline phosphatase, Lists of diseases, Liver injury, Primary sclerosing cholangitis, HIV disease progression rates, Fatty liver disease, Orphan drug, NASH, Liver, AASLD, HighTide, American Association, Association, 2021 Essex County Council election, Fast Track, ALP, PSC, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Dietary supplement, Patient

HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).

Key Points: 
  • HighTide Therapeutics, Inc. (HighTide), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 8, 2022).
  • Emerging evidence supports the bidirectional relationship between intestinal microbiota and liver health.
  • Dysbiosis has been associated with the pathogensis and progression of multiple metabolic diseases and chronic inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
  • Presentations at the Liver Meeting 2022 include:
    We are very pleased to share these data, said Liping Liu, Ph.D., founder and Chief Executive Officer of HighTide.

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunology, Congress, RNA transfection, Science, Multiple sclerosis, OLE, MRI, University, Treatment, GMG, Hypoesthesia, Antigen, Biomarker, SEL, Neuromyelitis optica spectrum disorder, MS, Gene editing, HIV disease progression rates, DBP, NMOSD, Inflammation, Interferon beta-1a, Learning, Senior, Company, Neurology, AFL, Phase, Central nervous system, Merck Millipore, BTK, Electronics, Lists of diseases, Intelligence, Nerve, Microglia, CNS, ARR, European Committee of the Regions, SLE, Merck Serono, Disease, Lupus, Patient, EDSS, MD, Doctor of Philosophy, Â, Research, RMS, University of Lille, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Merck, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.